Janssen Pharmaceuticals and its development partner Bayer announced results of two new real-world studies, which confirmed the positive benefit-risk profile of XARELTO (rivaroxaban) in treating venous thromboembolism (VTE), or blood clots, and minimising the risk of recurrence.
One study indicated that people with VTE taking XARELTO for longer than three months had a lower risk of VTE recurrence, without an increase in major bleeding, compared to those taking the medicine for only three months.
The second was the first read-out from Janssen's Post-Marketing Safety Surveillance (PMSS) study in VTE, which indicated the rates and patterns of major bleeding in people taking XARELTO for VTE in routine clinical practice were consistent with those reported in clinical trials.
VTE is a collective term, including deep vein thrombosis (DVT), a blood clot in a deep vein (usually the leg), and pulmonary embolism (PE), when a clot travels to the lung.
VTE impacts more than 900,000 people each year in the US, and one-third of these occurrences will be fatal.
Once a person experiences VTE, they are at an increased risk of it occurring again.
XARELTO is a prescription medicine used to cut down the risk of stroke and blood clots in people with atrial fibrillation, not caused by a heart valve problem. For those patients who are currently well managed on warfarin, there is limited information on how XARELTO and warfarin compare in reducing the risk of stroke.
It is also used to treat deep vein thrombosis and pulmonary embolism, and to help cut down the risk of these conditions occurring again.
XARELTO is additionally a prescription medicine for reducing the risk of forming a blood clot in the legs and lungs of people who have just had knee or hip replacement surgery.